Other states with Medicaid programs that cover obesity drugs have already started scaling back access over concerns about the expense
Weight loss by timeframe Month 1-2 (initial titration): 5-10 lbs lost Lower doses, body adapting Some appetite suppression Establishing habits Month 3-4 (dose escalation): 10-20 lbs total lost Significant appetite reduction Noticeable changes Plateau possible, keep titrating Month 5-8 (approaching maintenance dose): 20-35 lbs total lost Near or at full dose Maximum appetite suppression Consistent weekly loss (1-3 lbs) Month 9-12 (maintenance dose): 30-50 lbs total lost Full dose combination Continued steady loss Body composition improving Month 12-18 (long-term): 40-60+ lbs total lost (or 15-25% body weight) Exceptional responders: 60-80 lbs Weight stabilizing Focus shifts to maintenance Individual variation: Starting weight matters (higher = more absolute loss) Metabolism, activity level, diet affect results Some lose faster, some slower Consistency most important Comparison to semaglutide monotherapy Semaglutide 2.4mg alone (typical): 6 months: 20-30 lbs 12 months: 30-40 lbs 18 months: 35-45 lbs Average: 10-15% body weight CagriSema combination (typical): 6 months: 25-40 lbs 12 months: 40-60 lbs 18 months: 50-70+ lbs Average: 15-25% body weight Additional benefit: 50-75% more weight loss with combination Example: 240 lb person Semaglutide alone: Lose 24-36 lbs 204-216 lbs CagriSema combo: Lose 36-60 lbs 180-204 lbs Clinically significant difference See our peptides before and after results and how long do peptides take to work
Before the first injection, we chatted about my weight journey as well as my medical and social history (drinking, drugs, etc.) before drawing blood to send to the lab
Supportive in the treatment of chronic illness in general, IV glutathione is particularly effective in neurodegenerative conditions, cancer, liver disease, immunosuppressive states and persistent infections
BPC-157 delivers targeted local repair with additional gut-protective effects
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor
